312 related articles for article (PubMed ID: 25420363)
1. The effect of 5alpha-reductase inhibition with finasteride and dutasteride on bone mineral density in older men with benign prostatic hyperplasia.
Mačukat IR; Spanjol J; Orlič ZC; Butorac MZ; Marinovič M; Ćupič DF
Coll Antropol; 2014 Sep; 38(3):835-9. PubMed ID: 25420363
[TBL] [Abstract][Full Text] [Related]
2. The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial.
Matsumoto AM; Tenover L; McClung M; Mobley D; Geller J; Sullivan M; Grayhack J; Wessells H; Kadmon D; Flanagan M; Zhang GK; Schmidt J; Taylor AM; Lee M; Waldstreicher J;
J Urol; 2002 May; 167(5):2105-8. PubMed ID: 11956450
[TBL] [Abstract][Full Text] [Related]
3. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men.
Amory JK; Anawalt BD; Matsumoto AM; Page ST; Bremner WJ; Wang C; Swerdloff RS; Clark RV
J Urol; 2008 Jun; 179(6):2333-8. PubMed ID: 18423697
[TBL] [Abstract][Full Text] [Related]
4. Finasteride therapy does not alter bone turnover in men with benign prostatic hyperplasia--a Clinical Research Center study.
Tollin SR; Rosen HN; Zurowski K; Saltzman B; Zeind AJ; Berg S; Greenspan SL
J Clin Endocrinol Metab; 1996 Mar; 81(3):1031-4. PubMed ID: 8772571
[TBL] [Abstract][Full Text] [Related]
5. Comparative effect of finasteride and dutasteride on chromogranin A levels.
Sciarra A; Salciccia S; Nesi G; Cattarino S; Alfarone A; Gentilucci A; Gentile V
Anticancer Res; 2010 Nov; 30(11):4737-42. PubMed ID: 21115933
[TBL] [Abstract][Full Text] [Related]
6. 5α-reductase type 1 modulates insulin sensitivity in men.
Upreti R; Hughes KA; Livingstone DE; Gray CD; Minns FC; Macfarlane DP; Marshall I; Stewart LH; Walker BR; Andrew R
J Clin Endocrinol Metab; 2014 Aug; 99(8):E1397-406. PubMed ID: 24823464
[TBL] [Abstract][Full Text] [Related]
7. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
[TBL] [Abstract][Full Text] [Related]
8. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.
Kaplan SA; Chung DE; Lee RK; Scofield S; Te AE
Int J Clin Pract; 2012 Nov; 66(11):1052-5. PubMed ID: 23067029
[TBL] [Abstract][Full Text] [Related]
9. Effect of dutasteride on microvessel density in benign prostatic hyperplasia.
Sugie S; Mukai S; Tsukino H; Iwamoto H; Kobayashi T; Toda Y; Kamoto T
In Vivo; 2014; 28(3):355-9. PubMed ID: 24815838
[TBL] [Abstract][Full Text] [Related]
10. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.
Clark RV; Hermann DJ; Cunningham GR; Wilson TH; Morrill BB; Hobbs S
J Clin Endocrinol Metab; 2004 May; 89(5):2179-84. PubMed ID: 15126539
[TBL] [Abstract][Full Text] [Related]
11. Prolonged treatment with finasteride (a 5 alpha-reductase inhibitor) does not affect bone density and metabolism.
Matzkin H; Chen J; Weisman Y; Goldray D; Pappas F; Jaccard N; Braf Z
Clin Endocrinol (Oxf); 1992 Nov; 37(5):432-6. PubMed ID: 1283117
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous pharmacokinetic and pharmacodynamic analysis of 5α-reductase inhibitors and androgens by liquid chromatography tandem mass spectrometry.
Upreti R; Naredo G; Faqehi AM; Hughes KA; Stewart LH; Walker BR; Homer NZ; Andrew R
Talanta; 2015 Jan; 131():728-35. PubMed ID: 25281165
[TBL] [Abstract][Full Text] [Related]
13. Dutasteride: a potent dual inhibitor of 5-alpha-reductase for benign prostatic hyperplasia.
Rabasseda X
Drugs Today (Barc); 2004 Aug; 40(8):649-61. PubMed ID: 15510237
[TBL] [Abstract][Full Text] [Related]
14. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
Botto H; Lan O; Poulain JE; Comenducci A
Prog Urol; 2005 Dec; 15(6):1090-5. PubMed ID: 16429658
[TBL] [Abstract][Full Text] [Related]
15. A systematic review of the effects and mechanisms of preoperative 5α-reductase inhibitors on intraoperative haemorrhage during surgery for benign prostatic hyperplasia.
Zong HT; Peng XX; Yang CC; Zhang Y
Asian J Androl; 2011 Nov; 13(6):812-8. PubMed ID: 21892196
[TBL] [Abstract][Full Text] [Related]
16. Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.
Page ST; Hirano L; Gilchriest J; Dighe M; Amory JK; Marck BT; Matsumoto AM
J Urol; 2011 Jul; 186(1):191-7. PubMed ID: 21575967
[TBL] [Abstract][Full Text] [Related]
17. Dutasteride: a novel dual inhibitor of 5alpha-reductase for benign prostatic hyperplasia.
Djavan B; Milani S; Fong YK
Expert Opin Pharmacother; 2005 Feb; 6(2):311-7. PubMed ID: 15757426
[TBL] [Abstract][Full Text] [Related]
18. Consequences of switching 5alpha-reductase inhibitors on prostate specific antigen velocity.
Helfand BT; Blackwell RH; McVary KT
J Urol; 2010 Jul; 184(1):218-23. PubMed ID: 20483154
[TBL] [Abstract][Full Text] [Related]
19. 5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.
Dörsam J; Altwein J
Prostate Cancer Prostatic Dis; 2009; 12(2):130-6. PubMed ID: 19030020
[TBL] [Abstract][Full Text] [Related]
20. Do 5α-Reductase Inhibitors Raise Circulating Serum Testosterone Levels? A Comprehensive Review and Meta-Analysis to Explaining Paradoxical Results.
Traish AM; Krakowsky Y; Doros G; Morgentaler A
Sex Med Rev; 2019 Jan; 7(1):95-114. PubMed ID: 30098986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
